Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy

Trial Profile

Randomized Phase III Trial of Xcytrin (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Motexafin gadolinium (Primary)
  • Indications Cancer metastases; Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms SMART
  • Sponsors Pharmacyclics
  • Most Recent Events

    • 15 Mar 2009 Primary endpoint results published in International Journal of Radiation Oncology Biology Physics 73: 1069-1076, No. 4, 15 Mar 2009
    • 21 Jul 2006 Status change
    • 29 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top